3 to 12 years and 15 to 40 kg:
-Initial dose: mg/day orally in 2 to 3 divided doses
-Maintenance dose: to mg/kg/day
-The daily dose may be increased every 5 to 7 days in mg increments.
-There is little evidence that behavior improvement is further enhanced by doses greater than 6 mg/day.
-Limitation of use: Treatment should be reserved for patients with severe behavior problems and/or hyperactive children only after failure to respond to psychotherapy or medications (other than antipsychotics).
-Treatment of severe behavior problems in children, including combative, explosive hyperexcitability not accounted for by immediate provocation
-Short-term treatment of hyperactive children with excessive motor activity and accompanying conduct disorder with impulsivity, difficulty sustaining attention, aggressiveness, mood lability, and/or poor frustration tolerance.
Let your doctor know if you currently have or have ever been diagnosed with thyroid disease, breast cancer, seizures, liver disease, kidney disease, bipolar issues, an electrolyte imbalance, or heart conditions including long QT (LQTS) syndrome, and chest pain. These conditions may affect your ability to tolerate Haldol. People who have Parkinson's disease should not take Haldol. If you have ever had an extreme reaction or side effect to another medication prescribed to treat mental health issues, relay this information to your doctor. This drug is not recommended for elderly people experiencing dementia or related conditions as it may increase the risk of death.
The influence of renal impairment on the pharmacokinetics of haloperidol has not been evaluated. About one-third of a haloperidol dose is excreted in urine, mostly as metabolites. Less than 3% of administered haloperidol is eliminated unchanged in the urine. Haloperidol metabolites are not considered to make a significant contribution to its activity, although for the reduced metabolite of haloperidol, back-conversion to haloperidol cannot be fully ruled out. Even though impairment of renal function is not expected to affect haloperidol elimination to a clinically relevant extent, caution is advised in patients with renal impairment, and especially those with severe impairment, due to the long half-life of haloperidol and its reduced metabolite, and the possibility of accumulation (see section ).